

Digital Biomarkers Market by Type (Physiological, Vocal, Idiosyncratic), Therapy [Cardio, Onco (Lung, Breast Cancer), Mental Health, Neuro], Application [Clinical Research (Phase IV)], End User (Pharma & Biotech Companies, CROs) - Global Forecast to 2031

Market Report | 2026-04-06 | 402 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global digital biomarkers market is projected to reach USD 17.73 billion by 2031, growing from USD 7.41 billion in 2026 at a CAGR of 19.1%. The digital biomarkers market is being driven by the rapid evolution of data-driven clinical trials and the growing trend of integrating digital health technology into clinical trials. Pharmaceutical and biotech companies are increasingly using digital biomarkers in various stages of clinical trials to enable continuous and objective patient monitoring, thus improving data quality and endpoint accuracy. This is a part of a larger trend towards more efficient and patient-centric clinical trials, in which data from real-world sources plays a crucial role in determining the effectiveness of a drug. At the same time, there is a growing trend toward more decentralized clinical trials, in which data is collected more frequently by using remote data collection technology such as wearable devices and sensor technology. This is a part of a larger trend towards more digital biomarker software technology in clinical trials.

<https://mnmimg.marketsandmarkets.com/Images/digital-biomarker-market-img-overview.webp>

"By type, the physiological biomarkers segment is expected to account for the largest market share of the digital biomarkers market during the forecast period."

By type, the physiological biomarkers segment is expected to hold the largest share of the digital biomarkers market during the forecast period. This is mainly due to the widespread use of continuous physiological measures like heart rate, ECG, respiratory rate, and activity levels in various clinical research and patient care settings. Physiological biomarkers are scalable and are well

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

validated, making them more suitable for remote patient monitoring and chronic disease management. In addition, the growing trend of using software platforms and AI-based tools associated with wearable devices is further propelling their adoption, particularly in cardiovascular and metabolic conditions where continuous monitoring is critical in making clinical decisions. This is also evident from published research that states that physiological data streams like heart rate and activity levels are some of the most commonly used digital endpoints in clinical trials, mainly due to their objectivity and ability to provide high-frequency and real-world data. In addition, the move towards decentralized trials and RWE generation is also further solidifying their position in the field of digital biomarkers, as they allow for patient monitoring outside traditional clinical environments.

In June 2025, AliveCor, Inc. (US) partnered with the British Heart Foundation (UK), donating proceeds from its KardiaMobile 6L device to support cardiovascular research and promote the adoption of digital heart rhythm monitoring technologies. These examples further hint at the growing role of physiological digital biomarkers in advancing cardiac care and research.

"By end user, the hospitals & specialty clinics segment is expected to achieve the fastest growth during the forecast period."

By end user, the hospitals & specialty clinics segment is expected to witness the highest growth in the digital biomarkers market over the forecast period. The growth in this segment can be attributed to the rising adoption of digital biomarkers in hospitals and specialty clinics for real-time patient monitoring. Digital biomarkers are being increasingly integrated into the workflows of hospitals and specialty clinics for data-driven decision-making. Hospitals and specialty clinics are adopting wearable-enabled platforms and artificial intelligence-based analytics solutions for continuously monitoring physiological, cognitive, and behavioral changes in patients. Digital biomarkers help hospitals and specialty clinics in continuously monitoring patient data in real-time, thus helping in the early detection of changes in patient health. Moreover, the rising trend of value-based care is fueling the adoption of remote monitoring solutions in hospitals and specialty clinics. The rising prevalence of chronic diseases such as cardiovascular diseases, neurological disorders, and diabetes is also contributing to the growth of the digital biomarkers market in hospitals and specialty clinics. The rising trend of health information technology, which allows for seamless integration of digital biomarker solutions into electronic health records, is also fueling the growth of the digital biomarkers market in hospitals and specialty clinics.

"Asia Pacific to witness the highest growth rate during the forecast period."

The digital biomarkers market in Asia Pacific is growing rapidly, with the region witnessing high growth in the expansion of clinical research activities. The region is witnessing the incorporation of digital technologies into the healthcare infrastructure. Countries such as India, South Korea, Japan, and Australia are gaining importance as hubs for clinical research activities. Due to the improvement in the regulatory environment and the cost advantage, the pharmaceutical and biotech industries are increasingly using the Asia Pacific as a hub for conducting clinical research activities. As the pharmaceutical and biotech industries increasingly rely on digital technologies to conduct clinical research activities, the digital biomarkers market is growing rapidly.

Asia Pacific is witnessing the incorporation of digital technologies into the healthcare infrastructure. The region is witnessing the expansion of clinical research activities. In November 2025, Lunit Inc., a South Korean-based company, announced its collaboration with Labcorp to conduct research using digital pathology technology powered by artificial intelligence and expand access to imaging-based biomarkers for clinical and translational oncology research globally. Such developments indicate the potential of the region as a lucrative market for digital biomarkers.

The breakdown of primary participants is as follows:

- By Company Type - Tier 1 Companies: 60%, Tier 2 Companies: 30%, and Tier 3 Companies: 10%
- By Designation - C-level Executives: 30%, Director-level Personnel: 50%, and Other Designations: 20%
- By Region - North America: 45%, Europe: 20%, Asia Pacific: 25%, Rest of the world: 10%

IXICO PLC (UK), Ametris, LLC (US), and Empatica, Inc. (US) are some of the key players in the digital biomarkers market. The study includes an in-depth competitive analysis of these key players, their company profiles, recent developments, and key market strategies.

Research Coverage:

This research report categorizes the digital biomarkers market by type (physiological biomarkers, idiosyncratic biomarkers,

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

cognitive biomarkers, vocal biomarkers, and other biomarkers), therapeutic area {cardiovascular [atherosclerotic cardiovascular disease (ASCVD)/secondary prevention, heart failure (HF_rEF and HF_pEF), hypertension, atrial fibrillation (AF)/stroke prevention, pulmonary hypertension, and structural heart disease/interventional cardiology], oncology (solid tumors, hematologic malignancies), diabetes, mental health & behavioral health, respiratory disorders, lifestyle & wellness improvement, neurology, musculoskeletal disorders/pain management, women's health & reproductive health, and other diseases}, application, [clinical research applications (phase II, phase III, phase IV) and clinical care applications], end user [pharmaceutical and biotechnology companies, contract research organizations (CROs), hospitals and specialty clinics, and others (including research institutes, etc.)] and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa).

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the digital biomarkers market. A detailed analysis of the key industry players has been done to provide insights into their business overview; solutions and services; contracts, partnerships, agreements, product & service launches, mergers & acquisitions; and recent developments associated with the digital biomarkers market. Competitive analysis of upcoming startups in the digital biomarkers market ecosystem is covered in this report.

Reasons to Buy this Report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the digital biomarkers market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights into the following pointers:

- Analysis of key drivers (Expansion of smartphones, wearables, and connected health ecosystems; expansion of decentralized and remote clinical trials; rising prevalence of chronic diseases requiring continuous monitoring; advancements in AI and digital health analytics) restraints (Data privacy and security concerns related to health data, limited digital literacy and technology access among patients) opportunities (Increasing use of digital biomarkers in drug development and clinical trial endpoints, growth of precision medicine and personalized healthcare, emerging applications in neurological and mental health monitoring), challenges (Lack of standardized validation frameworks for digital biomarkers, regulatory uncertainty around digital endpoints and biomarker validation) influencing the growth of the digital biomarkers market
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and product & service launches in the digital biomarkers market
- Market Development: Comprehensive information about lucrative markets across varied regions
- Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the digital biomarkers market
- Competitive Assessment: In-depth assessment of market share, growth strategies, and service offerings of leading players, namely IXICO PLC (UK), Ametris, LLC (US), Empatica, Inc. (US), AliveCor, Inc. (US), CONNEQT Health (US), VivoSense (US), BioSensics (US), Lunit, Inc. (South Korea), among others, in the digital biomarkers market

Table of Contents:

1	INTRODUCTION	35
1.1	STUDY OBJECTIVES	35
1.2	MARKET DEFINITION	35
1.3	MARKET SCOPE	36
1.3.1	MARKET SEGMENTATION & REGIONAL SCOPE	36
1.3.2	INCLUSIONS & EXCLUSIONS	37
1.3.3	YEARS CONSIDERED	38
1.4	CURRENCY CONSIDERED	38
1.5	LIMITATIONS	39
1.6	STAKEHOLDERS	39

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2	EXECUTIVE SUMMARY	41
2.1	KEY INSIGHTS AND MARKET HIGHLIGHTS	41
2.2	KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS	43
2.3	DISRUPTIVE TRENDS SHAPING THE MARKET	44
2.4	HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS	45
2.5	SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST	46
3	PREMIUM INSIGHTS	47
3.1	DIGITAL BIOMARKERS MARKET OVERVIEW	47
3.2	DIGITAL BIOMARKERS MARKET, BY APPLICATION & REGION	48
3.3	DIGITAL BIOMARKERS MARKET: GEOGRAPHIC SNAPSHOT	48
4	MARKET OVERVIEW	49
4.1	INTRODUCTION	49
4.2	MARKET DYNAMICS	50
4.2.1	DRIVERS	50
4.2.1.1	Expansion of smartphones, wearables, and connected health ecosystems	50
4.2.1.2	Expansion of decentralized and remote clinical trials	51
4.2.1.3	Rising prevalence of chronic diseases that require continuous monitoring	52
4.2.1.4	Advancements in AI and digital health analytics	52
4.2.2	RESTRAINTS	53
4.2.2.1	Data privacy and cybersecurity concerns	53
4.2.2.2	Limited digital literacy and technology access among patients	53
4.2.3	OPPORTUNITIES	54
4.2.3.1	Increasing use in drug development and clinical trial endpoints	54
4.2.3.2	Growth of precision medicine and personalized healthcare	54
4.2.3.3	Emerging applications in neurological and mental health monitoring	55
4.2.4	CHALLENGES	55
4.2.4.1	Lack of standardized validation frameworks for digital biomarkers	55
4.2.4.2	Regulatory uncertainty around digital endpoints and biomarker validation	55
4.3	UNMET NEEDS AND WHITE SPACES	56
4.4	INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES	56
4.5	STRATEGIC MOVES BY TIER-1/2/3 PLAYERS	57
5	INDUSTRY TRENDS	58
5.1	PORTER'S FIVE FORCES ANALYSIS	58
5.1.1	BARGAINING POWER OF SUPPLIERS (MODERATE)	59
5.1.2	BARGAINING POWER OF BUYERS (HIGH)	59
5.1.3	THREAT OF SUBSTITUTES (MODERATE TO HIGH)	59
5.1.4	THREAT OF NEW ENTRANTS (MODERATE)	59
5.1.5	INTENSITY OF COMPETITIVE RIVALRY (HIGH)	60
5.2	MACROECONOMIC INDICATORS	60
5.2.1	INTRODUCTION	60
5.2.2	GDP TRENDS AND FORECAST	60
5.2.3	TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY	60
5.3	SUPPLY CHAIN ANALYSIS	61
5.4	ECOSYSTEM ANALYSIS	62
5.5	PRICING ANALYSIS	64
5.5.1	INDICATIVE PRICE FOR DIGITAL BIOMARKERS, BY KEY PLAYER (2025)	64
5.5.2	INDICATIVE PRICE FOR DIGITAL BIOMARKERS, BY REGION (2025)	65

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.6	KEY CONFERENCES AND EVENTS, 2026-2027	65
5.7	TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS	67
5.8	INVESTMENT AND FUNDING SCENARIO	67
5.9	CASE STUDY ANALYSIS	68
5.10	IMPACT OF 2025 US TARIFF ON DIGITAL BIOMARKERS MARKET	70
5.10.1	INTRODUCTION	70
5.10.2	KEY TARIFF RATES	71
5.10.3	PRICE IMPACT ANALYSIS	72
5.10.4	IMPACT ON COUNTRY/REGION	72
5.10.4.1	US	72
5.10.4.2	Europe	72
5.10.4.3	Asia Pacific	73
5.10.5	IMPACT ON END USERS	73
5.10.5.1	Pharmaceutical and biotechnology companies	73
5.10.5.2	Contract research organizations	73
5.10.5.3	Hospitals and specialty clinics	73
5.10.5.4	Others (research institutes, etc.)	74
6	CUSTOMER LANDSCAPE & BUYER BEHAVIOR	75
6.1	INTRODUCTION	75
6.2	DECISION-MAKING PROCESS	75
6.3	KEY STAKEHOLDERS AND BUYING EVALUATION CRITERIA	75
6.3.1	KEY STAKEHOLDERS IN BUYING PROCESS	75
6.3.2	BUYING CRITERIA	76
6.4	ADOPTION BARRIERS & INTERNAL CHALLENGES	77
6.5	UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES	78
6.5.1	UNMET NEEDS	78
6.5.2	END USER EXPECTATIONS	79
6.6	MARKET PROFITABILITY	79
7	REGULATORY LANDSCAPE	80
7.1	REGIONAL REGULATIONS AND COMPLIANCE	80
7.1.1	REGULATORY BODIES, GOVERNMENT AGENCIES, & OTHER ORGANIZATIONS	81
7.1.2	REGULATORY FRAMEWORK	85
7.1.2.1	North America	85
7.1.2.2	Europe	86
7.1.2.3	Asia Pacific	87
7.1.2.4	Latin America	88
7.1.2.5	Middle East & Africa	88
7.1.3	INDUSTRY STANDARDS	89
8	STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, AND AI ADOPTION	90
8.1	KEY EMERGING TECHNOLOGIES	90
8.1.1	WEARABLE SENSOR TECHNOLOGIES	90
8.1.2	ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING ANALYTICS	90
8.1.3	MOBILE HEALTH (MHEALTH) PLATFORMS AND SMARTPHONE SENSORS	90
8.2	COMPLEMENTARY TECHNOLOGIES	91
8.2.1	INTERNET OF MEDICAL THINGS (IOMT)	91
8.2.2	TELEHEALTH AND REMOTE PATIENT MONITORING	91

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.3 ADJACENT TECHNOLOGIES 91
- 8.3.1 DIGITAL THERAPEUTICS 91
- 8.3.2 DIGITAL PATHOLOGY AND IMAGING AI 92
- 8.4 TECHNOLOGY/PRODUCT ROADMAP 92
- 8.5 PATENT ANALYSIS 93
- 8.5.1 PATENT PUBLICATION TRENDS IN DIGITAL BIOMARKERS MARKET 93
- 8.5.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 94
- ?
- 8.6 FUTURE APPLICATIONS 96
- 8.6.1 AI-ENABLED INTELLIGENT SCREENING AND INTERPRETATION 97
- 8.6.2 CONTINUOUS AND PREDICTIVE HEALTH MONITORING APPLICATIONS 97
- 8.6.3 DECENTRALIZED, REMOTE, AND REAL-WORLD DATA ECOSYSTEMS 97
- 8.7 IMPACT OF AI/GEN AI ON DIGITAL BIOMARKERS MARKET 97
- 8.7.1 INTRODUCTION 97
- 8.7.2 MARKET POTENTIAL OF AI/GEN AI IN DIGITAL BIOMARKERS MARKET 98
- 8.7.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION 100
- 8.7.3.1 Early Alzheimer's detection using mobile-based cognitive assessment platforms 100
- 8.7.4 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 100
- 8.7.4.1 Digital health market 101
- 8.7.4.2 Remote patient monitoring market 101
- 8.7.4.3 Telehealth & telemedicine market 101
- 8.7.5 USER READINESS AND IMPACT ASSESSMENT 101
- 8.7.5.1 User readiness 101
- 8.7.5.1.1 User A: Pharmaceutical & biotechnology companies 101
- 8.7.5.1.2 User B: Contract research organizations (CROs) 102
- 8.7.5.2 Impact assessment 102
- 8.7.5.2.1 User A: Pharmaceutical & biotechnology companies 102
- 8.7.5.2.1.1 Implementation 102
- 8.7.5.2.1.2 Impact 102
- 8.7.5.2.2 User B: Contract research organizations 102
- 8.7.5.2.2.1 Implementation 102
- 8.7.5.2.2.2 Impact 103
- 9 DIGITAL BIOMARKERS MARKET, BY TYPE 104
- 9.1 INTRODUCTION 105
- 9.2 PHYSIOLOGICAL BIOMARKERS 105
- 9.2.1 SEGMENT LEADS MARKET ADOPTION THROUGH CLINICAL VALIDATION AND AI-DRIVEN ANALYTICS 105
- 9.3 IDIOSYNCRATIC BIOMARKERS 107
- 9.3.1 PRECISION MEDICINE DRIVEN THROUGH PERSONALIZED, INDIVIDUAL-LEVEL DATA INSIGHTS 107
- 9.4 COGNITIVE BIOMARKERS 109
- 9.4.1 ENABLE SCALABLE AND OBJECTIVE MEASUREMENT OF NEUROLOGICAL FUNCTION THROUGH ADVANCED ANALYTICS 109
- 9.5 VOCAL BIOMARKERS 110
- 9.5.1 AI-POWERED VOICE ANALYSIS ENABLES SCALABLE MENTAL HEALTH MONITORING 110
- 9.6 OTHER BIOMARKERS 112
- ?
- 10 DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA 114
- 10.1 INTRODUCTION 115
- 10.2 CARDIOVASCULAR 115

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.2.1 □ATHEROSCLEROTIC CARDIOVASCULAR DISEASE/SECONDARY PREVENTION □117
 - 10.2.1.1 □Continuous risk monitoring and predictive insights in cardiovascular disease management - key driver □117
 - 10.2.2 □HEART FAILURE (HFREF & HFPEF) □118
 - 10.2.2.1 □Demand driven by advanced early detection and remote monitoring in heart failure management □118
 - 10.2.3 □HYPERTENSION □119
 - 10.2.3.1 □Transforming blood pressure assessment from episodic to continuous monitoring □119
 - 10.2.4 □ATRIAL FIBRILLATION/STROKE PREVENTION □120
 - 10.2.4.1 □Unlocking subclinical AF identification via long-duration rhythm analytics □120
 - 10.2.5 □PULMONARY HYPERTENSION □121
 - 10.2.5.1 □Advancement of functional endpoint measurement beyond traditional walk tests to boost growth □121
 - 10.2.6 □STRUCTURAL HEART DISEASE/INTERVENTIONAL CARDIOLOGY □121
 - 10.2.6.1 □Remote post-procedural surveillance in structural heart interventions to drive segment □121
 - 10.3 □ONCOLOGY □122
 - 10.3.1 □SOLID TUMORS □124
 - 10.3.1.1 □BREAST CANCER □125
 - 10.3.1.1.1 □Segment driven by enhanced tumor characterization through AI-driven imaging and pathology analytics □125
 - 10.3.1.2 □LUNG CANCER □126
 - 10.3.1.2.1 □Enhanced immunotherapy response prediction using imaging biomarkers to boost growth □126
 - 10.3.1.3 □Prostate cancer □127
 - 10.3.1.3.1 □Segment growth propelled by reduced variability in cancer grading with quantitative digital pathology □127
 - 10.3.1.4 □COLORECTAL CANCER □127
 - 10.3.1.4.1 □Enhanced gastrointestinal oncology trials with decentralized functional endpoints - major driver □127
 - 10.3.1.5 □BRAIN TUMOR □128
 - 10.3.1.5.1 □Enhanced tumor monitoring with advanced MRI and volumetric analytics □128
 - 10.3.1.6 □OTHER SOLID TUMORS □129
 - 10.3.1.6.1 □Extension of digital biomarker utility across rare and heterogeneous tumor types to drive segment □129
 - 10.3.2 □HEMATOLOGIC MALIGNANCIES □130
 - 10.3.2.1 □LEUKEMIA □131
 - 10.3.2.1.1 □Enhanced MRD detection and quantification through AI-driven analytics to boost market □131
 - 10.3.2.2 □LYMPHOMA □132
 - 10.3.2.2.1 □Capturing immune response dynamics with continuous digital monitoring - key benefit □132
 - 10.3.2.3 □MULTIPLE MYELOMA □133
 - 10.3.2.3.1 □Segment growth driven by enhanced disease burden assessment with integrated imaging and pathology analytics □133
 - 10.3.2.4 □OTHER HEMATOLOGIC MALIGNANCIES □134
 - 10.3.2.4.1 □High-sensitivity endpoint generation in small patient populations to boost market □134
- 10.4 □DIABETES □135
 - 10.4.1 □CONTINUOUS MONITORING PLATFORMS EXPANDING INTO HOLISTIC CARDIOMETABOLIC RISK PREDICTION □135
- 10.5 □MENTAL HEALTH & BEHAVIORAL HEALTH □137
 - 10.5.1 □PASSIVE BEHAVIORAL AND VOICE DATA ENABLE SCALABLE OBJECTIVE CONDITION MONITORING □137
- 10.6 □RESPIRATORY DISORDERS □138
 - 10.6.1 □EARLY EXACERBATION DETECTION THROUGH CONTINUOUS MONITORING REDUCES HOSPITALIZATIONS AND COSTS □138
- 10.7 □LIFESTYLE & WELLNESS IMPROVEMENT □140
 - 10.7.1 □EXPANDING PREVENTIVE HEALTH THROUGH CONTINUOUS BEHAVIORAL DATA INSIGHTS □140
- 10.8 □NEUROLOGY □142
 - 10.8.1 □REGULATORY VALIDATION OF DIGITAL ENDPOINTS TO ACCELERATE EARLY DETECTION AND TRIAL ADOPTION □142
- 10.9 □MUSCULOSKELETAL DISORDERS/PAIN MANAGEMENT □144
 - 10.9.1 □EMPLOYER-BACKED DIGITAL CARE AND MOTION TRACKING TO DRIVE SCALABLE REHABILITATION SOLUTIONS □144

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.10	WOMEN'S HEALTH & REPRODUCTIVE HEALTH	146
10.10.1	ADDRESSING UNMET NEEDS THROUGH DATA-DRIVEN WOMEN'S HEALTH INSIGHTS	146
10.11	OTHER DISEASES	148
10.11.1	EXPANDING USE CASES TO DRIVE ADOPTION ACROSS CHRONIC AND UNDERSERVED CONDITIONS	148
11	DIGITAL BIOMARKERS MARKET, BY APPLICATION	149
11.1	INTRODUCTION	150
11.2	CLINICAL RESEARCH	150
11.2.1	PHASE II	152
11.2.1.1	Critical role in early-stage validation and risk reduction in clinical development	152
11.2.2	PHASE III	153
11.2.2.1	Regulatory-grade endpoint validation drives high-stakes clinical trial adoption	153
	?	
11.2.3	PHASE IV	154
11.2.3.1	Real-world evidence demand drives scalable continuous monitoring and reimbursement adoption	154
11.3	CLINICAL CARE	155
11.3.1	RISING CHRONIC DISEASE BURDEN DRIVING SHIFT TO CONTINUOUS PROACTIVE CARE	155
12	DIGITAL BIOMARKER MARKET, BY END USER	157
12.1	INTRODUCTION	158
12.2	PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES	158
12.2.1	CLINICAL TRIAL DRIVEN EFFICIENCY THROUGH HIGH-IMPACT DIGITAL ENDPOINTS	158
12.3	CONTRACT RESEARCH ORGANIZATIONS	159
12.3.1	END-TO-END DIGITAL TRIAL EXECUTION ENABLED THROUGH ADVANCED ANALYTICS	159
12.4	HOSPITALS & SPECIALTY CLINICS	160
12.4.1	ENHANCED CLINICAL OUTCOMES WITH REAL-TIME, DATA-DRIVEN CARE DELIVERY	160
12.5	OTHER END USERS	161
12.5.1	PUBLIC FUNDING AND REAL-WORLD DATA INITIATIVES ACCELERATE ECOSYSTEM-WIDE ADOPTION	161
13	DIGITAL BIOMARKERS MARKET, BY REGION	163
13.1	INTRODUCTION	164
13.2	NORTH AMERICA	164
13.2.1	MACROECONOMIC OUTLOOK FOR NORTH AMERICA	165
13.2.2	US	170
13.2.2.1	Regulatory advancements and pharma-tech convergence drive market growth	170
13.2.3	CANADA	174
13.2.3.1	Increasing integration of AI-driven screening and remote monitoring to drive market	174
13.3	EUROPE	178
13.3.1	MACROECONOMIC OUTLOOK FOR EUROPE	179
13.3.2	GERMANY	183
13.3.2.1	Strong clinical trial ecosystem and progressive digital health regulation to drive market	183
13.3.3	FRANCE	187
13.3.3.1	Strong clinical trial base and evidence-driven regulatory pathways to drive market	187
13.3.4	UK	191
13.3.4.1	Strong NHS data infrastructure and push for data-enabled clinical trials to drive market	191
13.3.5	ITALY	195
13.3.5.1	Strong clinical research activity and oncology-driven demand to shape market growth	195

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

13.3.6	SPAIN	199
13.3.6.1	Strong clinical trial leadership and high domestic research concentration to drive market	199
13.3.7	REST OF EUROPE	203
13.4	LATIN AMERICA	208
13.4.1	MACROECONOMIC OUTLOOK FOR LATIN AMERICA	208
13.4.2	BRAZIL	212
13.4.2.1	Expanding digital health ecosystem and regulatory reforms to drive digital biomarkers adoption	212
13.4.3	MEXICO	216
13.4.3.1	Growing clinical trial participation and digital transformation to drive digital biomarkers adoption	216
13.4.4	REST OF LATIN AMERICA	220
13.5	ASIA PACIFIC	224
13.5.1	ASIA PACIFIC: CLINICAL TRIAL INITIATIONS IN 2014 AND 2024	225
13.5.2	MACROECONOMIC OUTLOOK FOR ASIA PACIFIC	225
13.5.3	CHINA	230
13.5.3.1	Expanding clinical trial leadership and advancing digital health ecosystem to drive market	230
13.5.4	JAPAN	234
13.5.4.1	Declining clinical trial activity despite strong legacy position to impact market	234
13.5.5	INDIA	238
13.5.5.1	Rapid clinical trial growth, cost advantages, and regulatory reforms to drive market	238
13.5.6	AUSTRALIA	242
13.5.6.1	Strong early-phase trial capabilities and advanced research infrastructure to drive market	242
13.5.7	SOUTH KOREA	246
13.5.7.1	Steady clinical trial growth and strong innovation ecosystem to drive market	246
13.5.8	REST OF ASIA PACIFIC	250
13.6	MIDDLE EAST & AFRICA	255
13.6.1	MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA	255
13.6.2	GCC COUNTRIES	260
13.6.2.1	Strong digital health transformation and growing clinical research activity to drive adoption	260
13.6.3	SAUDI ARABIA	264
13.6.3.1	Expanding clinical research activity and government-led initiatives to drive market	264
13.6.4	UAE	268
13.6.4.1	Advancing digital health innovation and strategic collaborations - key growth drivers	268
13.6.5	OTHER GCC COUNTRIES	272
13.6.5.1	Regulatory initiatives, national health visions, and digital health infrastructure boost market growth	272
13.6.6	SOUTH AFRICA	276
13.6.6.1	Leading clinical research hub in Africa with strong infrastructure	276
13.6.7	REST OF MIDDLE EAST & AFRICA	280
14	COMPETITIVE LANDSCAPE	285
14.1	OVERVIEW	285
14.2	KEY PLAYER STRATEGIES/RIGHT TO WIN	285
14.2.1	OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DIGITAL BIOMARKERS MARKET	286
14.3	REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS	288
14.4	MARKET SHARE ANALYSIS, 2025	289
14.5	BRAND COMPARISON	292
14.6	COMPANY VALUATION & FINANCIAL METRICS	293
14.6.1	FINANCIAL METRICS	293
14.6.2	COMPANY VALUATION	293

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

14.7	COMPANY EVALUATION MATRIX	294
14.7.1	STARS	294
14.7.2	EMERGING LEADERS	294
14.7.3	PERVASIVE PLAYERS	294
14.7.4	PARTICIPANTS	294
14.7.5	COMPANY FOOTPRINT: KEY PLAYERS, 2025	296
14.7.5.1	Company footprint	296
14.7.5.2	Region footprint	297
14.7.5.3	Type footprint	298
14.7.5.4	Therapeutic area footprint	299
14.7.5.5	Application footprint	300
14.7.5.6	End user footprint	301
14.8	COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025	302
14.8.1	PROGRESSIVE COMPANIES	302
14.8.2	RESPONSIVE COMPANIES	302
14.8.3	DYNAMIC COMPANIES	302
14.8.4	STARTING BLOCKS	302
14.8.5	COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024	304
14.8.5.1	Detailed list of key startups/SMEs	304
14.8.5.2	Competitive benchmarking of startups/SMEs	305
14.9	COMPETITIVE SCENARIO	306
14.9.1	PRODUCT/SERVICE LAUNCHES & APPROVALS	306
14.9.2	DEALS	307
14.9.3	OTHER DEVELOPMENTS	308
	?	
15	COMPANY PROFILES	309
15.1	KEY PLAYERS	309
15.1.1	IXICO PLC	309
15.1.1.1	Business overview	309
15.1.1.2	Products offered	310
15.1.1.3	Recent developments	311
15.1.1.3.1	Product launches/approvals	311
15.1.1.3.2	Deals	311
15.1.1.4	MnM view	312
15.1.1.4.1	Key strengths	312
15.1.1.4.2	Strategic choices	313
15.1.1.4.3	Weaknesses and competitive threats	313
15.1.2	AMETRIS, LLC	314
15.1.2.1	Business overview	314
15.1.2.2	Products Offered	315
15.1.2.3	Recent developments	315
15.1.2.3.1	Product launches/enhancements	315
15.1.2.3.2	Deals	316
15.1.2.4	MnM view	318
15.1.2.4.1	Key strengths	318
15.1.2.4.2	Strategic choices	318
15.1.2.4.3	Weaknesses and competitive threats	318

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.1.3 EMPATICA INC. 319
 - 15.1.3.1 Business overview 319
 - 15.1.3.2 Products/Solutions offered 320
 - 15.1.3.3 Recent developments 321
 - 15.1.3.3.1 Product launches/approvals 321
 - 15.1.3.3.2 Deals 322
 - 15.1.3.4 MnM view 323
 - 15.1.3.4.1 Key strengths 323
 - 15.1.3.4.2 Strategic choices 323
 - 15.1.3.4.3 Weaknesses and competitive threats 323
- 15.1.4 ALIVECOR, INC. 324
 - 15.1.4.1 Business overview 324
 - 15.1.4.2 Products offered 325
 - 15.1.4.3 Recent developments 326
 - 15.1.4.3.1 Product launches/approvals 326
 - 15.1.4.3.2 Deals 326
 - 15.1.4.4 MnM view 328
 - 15.1.4.4.1 Key strengths 328
 - 15.1.4.4.2 Strategic choices 328
 - 15.1.4.4.3 Weaknesses and competitive threats 328
- 15.1.5 CONNEQT HEALTH 329
 - 15.1.5.1 Business overview 329
 - 15.1.5.2 Products offered 331
 - 15.1.5.3 Recent developments 331
 - 15.1.5.3.1 Product enhancements/approvals 331
 - 15.1.5.4 MnM view 332
 - 15.1.5.4.1 Key strengths 332
 - 15.1.5.4.2 Strategic choices 332
 - 15.1.5.4.3 Weaknesses and competitive threats 332
- 15.1.6 VIVOSENSE 333
 - 15.1.6.1 Business overview 333
 - 15.1.6.2 Products offered 333
 - 15.1.6.2.1 Other developments 334
- 15.1.7 BIOSENSICS 335
 - 15.1.7.1 Business overview 335
 - 15.1.7.2 Products offered 336
 - 15.1.7.3 Recent developments 336
 - 15.1.7.3.1 Product launches/approvals 336
 - 15.1.7.3.2 Deals 337
- 15.1.8 LUNIT INC. 338
 - 15.1.8.1 Business overview 338
 - 15.1.8.2 Products offered 340
 - 15.1.8.3 Recent developments 341
 - 15.1.8.3.1 Product launches/approvals 341
 - 15.1.8.3.2 Deals 342
- 15.1.9 AKILI, INC. 345
 - 15.1.9.1 Business overview 345

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

15.1.9.2	Products offered	345
15.1.9.3	Recent developments	346
15.1.9.3.1	Deals	346
15.1.10	QUIBIM	347
15.1.10.1	Business overview	347
15.1.10.2	Products offered	347
15.1.10.3	Recent developments	349
15.1.10.3.1	Product launches/approvals/enhancements	349
15.1.10.3.2	Deals	350
15.1.11	CLARIO	351
15.1.11.1	Business overview	351
15.1.11.2	Products offered	352
15.1.11.3	Recent developments	353
15.1.11.3.1	Deals	353
?		
15.1.12	PROSCIA INC.	356
15.1.12.1	Business overview	356
15.1.12.2	Products offered	357
15.1.12.3	Recent developments	358
15.1.12.3.1	Product launches/approvals	358
15.1.12.3.2	Deals	358
15.1.13	KONEKSA HEALTH	361
15.1.13.1	Business overview	361
15.1.13.2	Products offered	362
15.1.13.3	Recent developments	363
15.1.13.3.1	Product launches	363
15.1.13.3.2	Deals	364
15.1.14	LINUS HEALTH	365
15.1.14.1	Business overview	365
15.1.14.2	Products offered	366
15.1.14.3	Recent developments	366
15.1.14.3.1	Product launches/approvals	366
15.1.14.3.2	Deals	367
15.2	OTHER PLAYERS	369
15.2.1	SONDE HEALTH, INC.	369
15.2.2	ALTOIDA	370
15.2.3	IMVARIA INC.	371
15.2.4	CUMULUS NEUROSCIENCE LIMITED	372
15.2.5	DELVE HEALTH	373
15.2.6	FEEL THERAPEUTICS	374
15.2.7	NANOWEAR INC.	375
15.2.8	EXOSYSTEMS	376
15.2.9	CARDIOSIGNAL	377
15.2.10	IMAGENE AI LTD.	378
15.2.11	NEUROTRACK TECHNOLOGIES, INC.	379
16	RESEARCH METHODOLOGY	380
16.1	RESEARCH APPROACH	380

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

16.1.1	SECONDARY RESEARCH	381
16.1.1.1	Key data from secondary sources	382
16.1.2	PRIMARY RESEARCH	382
16.1.2.1	Primary sources	383
16.1.2.2	Key data from primary sources	384
16.1.2.3	Breakdown of primaries	384
16.1.2.4	Insights from primary experts	385
?		
16.2	RESEARCH METHODOLOGY DESIGN	385
16.3	MARKET SIZE ESTIMATION	386
16.4	MARKET BREAKDOWN DATA TRIANGULATION	391
16.5	MARKET SHARE ESTIMATION	392
16.6	STUDY ASSUMPTIONS	392
16.7	RESEARCH LIMITATIONS	393
16.7.1	METHODOLOGY-RELATED LIMITATIONS	393
16.8	RISK ASSESSMENT	393
17	APPENDIX	394
17.1	DISCUSSION GUIDE	394
17.2	KNOWLEDGESTORE: MARKET SAND MARKETS' SUBSCRIPTION PORTAL	398
17.3	CUSTOMIZATION OPTIONS	400
17.4	RELATED REPORTS	400
17.5	AUTHOR DETAILS	401

Digital Biomarkers Market by Type (Physiological, Vocal, Idiosyncratic), Therapy [Cardio, Onco (Lung, Breast Cancer), Mental Health, Neuro], Application [Clinical Research (Phase IV)], End User (Pharma & Biotech Companies, CROs) - Global Forecast to 2031

Market Report | 2026-04-06 | 402 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com

Zip Code*

Country*

Date

2026-06-08

Signature

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com